Q4 2023 13F Holders as of 31 Dec 2023
-
Type / Class
-
Equity / Common Stock, $0.0001 par value per share
-
Shares outstanding
-
42,194,093
-
Total 13F shares
-
32,126,860
-
Share change
-
+2,268,590
-
Total reported value
-
$650,570,328
-
Put/Call ratio
-
16%
-
Price per share
-
$20.25
-
Number of holders
-
114
-
Value change
-
+$49,625,202
-
Number of buys
-
72
-
Number of sells
-
39
Institutional Holders of Tarsus Pharmaceuticals, Inc. - Common Stock, $0.0001 par value per share (TARS) as of Q4 2023
As of 31 Dec 2023,
Tarsus Pharmaceuticals, Inc. - Common Stock, $0.0001 par value per share (TARS) was held by
114 institutional
shareholders
that filed Form 13F with the SEC.
Together, they reported ownership of
32,126,860 shares.
The largest 10 holders included
RTW INVESTMENTS, LP, BlackRock Inc., Cormorant Asset Management, LP, TANG CAPITAL MANAGEMENT LLC, MORGAN STANLEY, COWEN AND COMPANY, LLC, Frazier Life Sciences Management, L.P., Vivo Capital, LLC, VANGUARD GROUP INC, and PERCEPTIVE ADVISORS LLC.
This page lists
114
institutional shareholders reporting positions in this security
for the Q4 2023 filing period.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price
|
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.